메뉴 건너뛰기




Volumn 25, Issue 7, 2007, Pages 594-598

Dose-intense PEFG (cisplatin, epirubicin, 5-fluorouracil, gemcitabine) in advanced pancreatic adenocarcinoma: A dose-finding study

Author keywords

5 Fluorouracil; Chemotherapy; Cisplatin; Epirubicin; Gemcitabine; Metastatic disease; Pancreatic cancer

Indexed keywords

CISPLATIN; EPIRUBICIN; FLUOROURACIL; GEMCITABINE;

EID: 36248954607     PISSN: 07357907     EISSN: 15324192     Source Type: Journal    
DOI: 10.1080/07357900701359932     Document Type: Article
Times cited : (14)

References (16)
  • 1
    • 0029816590 scopus 로고    scopus 로고
    • Chemotherapy improves survival and quality of life in advanced pancreatic and biliary cancer
    • Glimelius, B.; Hoffmann, K.; Sjoeden, P.-O.; et al. Chemotherapy improves survival and quality of life in advanced pancreatic and biliary cancer. Ann. Oncol. 1996, 7, 593-600.
    • (1996) Ann. Oncol , vol.7 , pp. 593-600
    • Glimelius, B.1    Hoffmann, K.2    Sjoeden, P.-O.3
  • 2
    • 8244254377 scopus 로고    scopus 로고
    • Improvement in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: A randomized trial
    • Burris, III, H.A.; Moore, M.J.; Andersen, J.; Green, M.R.; Rothenberg, M.L.; Modiano, M.R.; et al. Improvement in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. J. Clin. Oncol. 1997, 15, 2403-2413.
    • (1997) J. Clin. Oncol , vol.15 , pp. 2403-2413
    • Burris III, H.A.1    Moore, M.J.2    Andersen, J.3    Green, M.R.4    Rothenberg, M.L.5    Modiano, M.R.6
  • 3
    • 0036682041 scopus 로고    scopus 로고
    • Phase III study of gemcitabine in combination with fluorouracil versus gemcitabine alone in patients with advanced pancreatic carcinoma: Eastern Cooperative Oncology Group Trial E2297
    • Berlin, J.D.; Catalano, P.; Thomas, J.P.; Kugler, J.W.; Haller, D.G.; Benson, A.B. III. Phase III study of gemcitabine in combination with fluorouracil versus gemcitabine alone in patients with advanced pancreatic carcinoma: Eastern Cooperative Oncology Group Trial E2297. J. Clin. Oncol. 2002, 20, 3270-3275.
    • (2002) J. Clin. Oncol , vol.20 , pp. 3270-3275
    • Berlin, J.D.1    Catalano, P.2    Thomas, J.P.3    Kugler, J.W.4    Haller, D.G.5    Benson III, A.B.6
  • 4
    • 0141688333 scopus 로고    scopus 로고
    • Comparison of gemcitabine versus the matrix metalloproteinase inhibitor BAY 12-9566 in patients with advanced or metastatic adenocarcinoma of the pancreas: A Phase III trial of the National Cancer Institute of Canada Clinical Trials Group
    • Moore, M.J.; Hamm, J.; Dancey, J.; Eisenberg, P.D.; Dagenais, M.; Fields, A.; et al. Comparison of gemcitabine versus the matrix metalloproteinase inhibitor BAY 12-9566 in patients with advanced or metastatic adenocarcinoma of the pancreas: a Phase III trial of the National Cancer Institute of Canada Clinical Trials Group. J. Clin. Oncol. 2003, 21, 3296-3302.
    • (2003) J. Clin. Oncol , vol.21 , pp. 3296-3302
    • Moore, M.J.1    Hamm, J.2    Dancey, J.3    Eisenberg, P.D.4    Dagenais, M.5    Fields, A.6
  • 5
    • 4644327989 scopus 로고    scopus 로고
    • Irinotecan plus gemcitabine results in no survival advantage compared with gemcitabine monotherapy in patients with locally advanced or metastatic pancreatic cancer despite increased tumor response rate
    • Rocha Lima, C.M.S.; Green, M.R.; Rotche, R.; Miller, W.H., Jr; Jeffrey, G.M.; Cisar, L.A.; et al. Irinotecan plus gemcitabine results in no survival advantage compared with gemcitabine monotherapy in patients with locally advanced or metastatic pancreatic cancer despite increased tumor response rate. J. Clin. Oncol. 2004, 22, 3776-3783.
    • (2004) J. Clin. Oncol , vol.22 , pp. 3776-3783
    • Rocha Lima, C.M.S.1    Green, M.R.2    Rotche, R.3    Miller Jr, W.H.4    Jeffrey, G.M.5    Cisar, L.A.6
  • 6
    • 0037100983 scopus 로고    scopus 로고
    • A double-blind placebo-controlled, randomised study comparing gemcitabine and marimastat with gemcitabine and placebo as first line therapy in patients with advanced pancreatic cancer
    • Bramhall, S.R.; Schultz, J.; Nemunaitis, J.; Brown, P.D.; Baillet, M.; Buckels, J.A.C. A double-blind placebo-controlled, randomised study comparing gemcitabine and marimastat with gemcitabine and placebo as first line therapy in patients with advanced pancreatic cancer. Br. J. Cancer 2002, 87, 161-167.
    • (2002) Br. J. Cancer , vol.87 , pp. 161-167
    • Bramhall, S.R.1    Schultz, J.2    Nemunaitis, J.3    Brown, P.D.4    Baillet, M.5    Buckels, J.A.C.6
  • 7
    • 0035424135 scopus 로고    scopus 로고
    • Bramhall, S.R.; Rosemurgy, A.; Brown, P.D.; Bowry, C.; Buckels, J.A.; for the Marimastat Pancreatic Cancer Study Group. Marimastat as first-line therapy for patients with unresectable pancreatic cancer: a randomized trial. J. Clin. Oncol. 2001, 19, 3477-3455.
    • Bramhall, S.R.; Rosemurgy, A.; Brown, P.D.; Bowry, C.; Buckels, J.A.; for the Marimastat Pancreatic Cancer Study Group. Marimastat as first-line therapy for patients with unresectable pancreatic cancer: a randomized trial. J. Clin. Oncol. 2001, 19, 3477-3455.
  • 8
    • 33748445708 scopus 로고    scopus 로고
    • Randomized Phase III trial of gemcitabine plus cisplatin compared with gemcitabine alone in advanced pancreatic cancer
    • Heinemann, V.; Quietzsch, D.; Gieseler, F.; Gonnermann, N.; Schonekas, H.; Rost, A.; et al. Randomized Phase III trial of gemcitabine plus cisplatin compared with gemcitabine alone in advanced pancreatic cancer. J. Clin. Oncol. 2006, 24, 3946-3952.
    • (2006) J. Clin. Oncol , vol.24 , pp. 3946-3952
    • Heinemann, V.1    Quietzsch, D.2    Gieseler, F.3    Gonnermann, N.4    Schonekas, H.5    Rost, A.6
  • 9
    • 2342645506 scopus 로고    scopus 로고
    • Phase III trial of gemcitabine plus tipifarnib compared with gemcitabine plus placebo in advanced pancreatic cancer
    • Van Cutsem, E.; van de Velde, H.; Karasek, P.; Oettle, H.; Vervenne, W.L.; Szawlowski, A.; et al. Phase III trial of gemcitabine plus tipifarnib compared with gemcitabine plus placebo in advanced pancreatic cancer. J. Clin. Oncol. 2004, 22, 1430-1438.
    • (2004) J. Clin. Oncol , vol.22 , pp. 1430-1438
    • Van Cutsem, E.1    van de Velde, H.2    Karasek, P.3    Oettle, H.4    Vervenne, W.L.5    Szawlowski, A.6
  • 10
    • 19944409357 scopus 로고    scopus 로고
    • Gemcitabine versus cisplatin, epirubicin, 5-fluorouracil, gemcitabine in advanced pancreatic cancer: A Phase III trial
    • Reni, M.; Cordio, S.; Milandri, C.; et al. Gemcitabine versus cisplatin, epirubicin, 5-fluorouracil, gemcitabine in advanced pancreatic cancer: a Phase III trial. Lancet Oncol. 2005, 6, 369-376.
    • (2005) Lancet Oncol , vol.6 , pp. 369-376
    • Reni, M.1    Cordio, S.2    Milandri, C.3
  • 11
    • 34249933404 scopus 로고    scopus 로고
    • Moore, M.J.; Goldstein, D.; Hamm, J.; et al. Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer. A phase III trial of the National Cancer Institute of Canada Clinical Trials Group. J. Clin. Oncol. 2007, 25, published ahead of print on April 23, 2007.
    • Moore, M.J.; Goldstein, D.; Hamm, J.; et al. Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer. A phase III trial of the National Cancer Institute of Canada Clinical Trials Group. J. Clin. Oncol. 2007, 25, published ahead of print on April 23, 2007.
  • 12
    • 0035873947 scopus 로고    scopus 로고
    • Definitive results of a Phase II trial of PEF-G (cisplatin, epirubicin, 5-fluorouracil continuous infusion, gemcitabine) in Stage IV pancreatic adenocarcinoma
    • Reni, M.; Passoni, P.; Panucci, M.G.; et al. Definitive results of a Phase II trial of PEF-G (cisplatin, epirubicin, 5-fluorouracil continuous infusion, gemcitabine) in Stage IV pancreatic adenocarcinoma. J. Clin. Oncol. 2001, 19, 2679-2686.
    • (2001) J. Clin. Oncol , vol.19 , pp. 2679-2686
    • Reni, M.1    Passoni, P.2    Panucci, M.G.3
  • 13
    • 33750293070 scopus 로고    scopus 로고
    • Quality of life assessment in advanced pancreatic adenocarcinoma: Results from a Phase III randomized trial
    • Reni, M.; Bonetto, E.; Cordio, S.; et al. Quality of life assessment in advanced pancreatic adenocarcinoma: Results from a Phase III randomized trial. Pancreatology 2006, 6, 454-463.
    • (2006) Pancreatology , vol.6 , pp. 454-463
    • Reni, M.1    Bonetto, E.2    Cordio, S.3
  • 14
    • 0003412931 scopus 로고    scopus 로고
    • International Union Against Cancer
    • Sobin, L.H, Wittekind, C, eds, 5th ed, New York: Wiley-Liss
    • Sobin, L.H.; Wittekind, C.; eds. International Union Against Cancer. TNM classification of malignant tumours, 5th ed.; New York: Wiley-Liss, 1997.
    • (1997) TNM classification of malignant tumours
  • 15
    • 23844495516 scopus 로고    scopus 로고
    • Final results of a prospective trial of a PEFG (cisplatin, epirubicin, 5-fluorouracil, gemcitabine) regimen followed by radiotherapy after curative surgery for pancreatic adenocarcinoma
    • Reni, M.; Passoni, P.; Bonetto, E.; et al. Final results of a prospective trial of a PEFG (cisplatin, epirubicin, 5-fluorouracil, gemcitabine) regimen followed by radiotherapy after curative surgery for pancreatic adenocarcinoma. Oncology 2005, 68, 239-245.
    • (2005) Oncology , vol.68 , pp. 239-245
    • Reni, M.1    Passoni, P.2    Bonetto, E.3


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.